188 related articles for article (PubMed ID: 30297488)
1. Dermatomyositis with anti-TIF1-γ antibodies.
De Greef A; Marot L; Yildiz H; Baeck M
BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30297488
[No Abstract] [Full Text] [Related]
2. Amyopathic dermatomyositis with anti-TIF1 gamma antibodies.
Schiffmann ML; Warneke VS; Ehrchen J
J Dtsch Dermatol Ges; 2018 Jan; 16(1):76-78. PubMed ID: 29232033
[No Abstract] [Full Text] [Related]
3. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
5. Anti-TIF1-γ autoantibodies-positive dermatomyositis: where is the malignancy?
Zachou A; Zouvelou V; Papadimas GK; Rentzos M; Papadopoulos C
Rheumatology (Oxford); 2018 Apr; 57(4):756. PubMed ID: 28968891
[No Abstract] [Full Text] [Related]
6. Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria.
Didona D; Juratli HA; Scarsella L; Keber U; Eming R; Hertl M
Eur J Dermatol; 2020 Jun; 30(3):279-288. PubMed ID: 32666928
[TBL] [Abstract][Full Text] [Related]
7. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy.
Dourmishev LA
Folia Med (Plovdiv); 2017 Mar; 59(1):7-13. PubMed ID: 28384112
[TBL] [Abstract][Full Text] [Related]
9. Dermatomyositis with anti-OJ antibody.
Noda S; Asano Y; Tamaki Z; Hirabayashi M; Yamamoto M; Takekoshi T; Hoashi T; Sugaya M; Morimoto R; Etoh T; Kaji K; Fujimoto M; Kuwana M; Sato S
Rheumatol Int; 2011 Dec; 31(12):1673-5. PubMed ID: 21132548
[No Abstract] [Full Text] [Related]
10. Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.
Hori H; Ozeki Y; Kobashigawa T; Futsuhara K; Tanaka A; Watanabe E; Yabe H; Yago T; Fukuchi T; Sugawara H; Kotake S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):62-68. PubMed ID: 33269651
[TBL] [Abstract][Full Text] [Related]
11. Predominance of CD4+ T cells and Th2 cytokines in the pericardial fluid of a dermatomyositis patient with cardiac tamponade.
Martínez A; Vilá LM; Ríos-Olivares E
Clin Exp Rheumatol; 2004; 22(1):135. PubMed ID: 15005021
[No Abstract] [Full Text] [Related]
12. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
13. Anti-transcriptional intermediary factor 1-γ antibody as a biomarker in patients with dermatomyositis.
Shimizu K; Kobayashi T; Kano M; Hamaguchi Y; Takehara K; Matsushita T
J Dermatol; 2020 Jan; 47(1):64-68. PubMed ID: 31638280
[TBL] [Abstract][Full Text] [Related]
14. Subtle erythema of the forehead.
McCarthy S; Murray D; Watson R; Murphy M; Dvorakova V
Clin Exp Dermatol; 2020 Jun; 45(4):470-471. PubMed ID: 31671474
[No Abstract] [Full Text] [Related]
15. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
Fiorentino DF; Mecoli CA; Rosen MC; Chung LS; Christopher-Stine L; Rosen A; Casciola-Rosen L
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040440
[TBL] [Abstract][Full Text] [Related]
16. Ovoid palatal patch: a clue to anti-TIF1γ dermatomyositis.
Franciosi E; Blankenship K; Houk L; Rashighi M
BMJ Case Rep; 2020 Apr; 13(4):. PubMed ID: 32332045
[TBL] [Abstract][Full Text] [Related]
17. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients.
García-Doval I; Cruces M
Dermatology; 2004; 209(3):247-8. PubMed ID: 15459546
[No Abstract] [Full Text] [Related]
18. Dermatomyositis-like eruption associated with hydroxyurea therapy: a premalignant condition?
de Unamuno-Bustos B; Ballester-Sánchez R; Sabater Marco V; Vilata-Corell JJ
Actas Dermosifiliogr; 2014 Nov; 105(9):876-8. PubMed ID: 24666578
[No Abstract] [Full Text] [Related]
19. Primary Sjögren's syndrome with myalgia mimicking dermatomyositis.
Saito S; Togashi A; Kaneko F; Yamamoto T; Uchida T; Oyama N
J Dermatol; 2010 Sep; 37(9):837-9. PubMed ID: 20883374
[No Abstract] [Full Text] [Related]
20. Anti-Ro 52 positive dermatomyositis presenting as rapidly progressive interstitial lung disease.
Conway R; O'Donnell R; Fahy R; Doran MF; Cunnane G; O'Shea FD
QJM; 2014 Jul; 107(7):593-4. PubMed ID: 24336848
[No Abstract] [Full Text] [Related]
[Next] [New Search]
